Composing Compound Libraries for Hit Discovery – Rationality-Driven Preselection or Random Choice by Structural Diversity?

References

• Levy SB , MarshallB. Antibacterial resistance worldwide: causes, challanges and respones. Nat. Med.10 (12), S122–S129 (2004).
   PubMed Web of Science ®Google Scholar
• Kaitin KI , DimasiJA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009.Clin. Pharmacol. Ther.89 (2), 183–188 (2011).
   PubMed Web of Science ®Google Scholar
• Talbot GH . What is in the pipeline for Gram-negative pathogens?Expert Rev. Anti Infect. Ther.6 (1), 39–49 (2008).
   PubMed Web of Science ®Google Scholar
• Livermore DM . Has the era of untreatable infections arrived?J. Antimicrob. Chemother.64 (4), 29–36 (2009).
   Web of Science ®Google Scholar
• Lambert PA . Mechanism of antibiotic resistance in Pseudomonas aeruginosa. J. R. Soc. Med.95, 22–26 (2002).
   PubMed Web of Science ®Google Scholar
• Nikaido H. Prevention of drug access to bacterial targets - permeability barriers and active efflux. Science. 264 (5157), 382–388 (1994).
   PubMed Web of Science ®Google Scholar
• Rivers EC , ManceraRL. New anti-tuberculosis drugs in clinical trials with novel mechanisms of action. Drug Discov. Today13 (23-24), 1090–1098 (2008).
   PubMed Web of Science ®Google Scholar
• Barrett CT , BarrettJF. Antibacterials: are the new entries enough to deal with the emerging resistance problems?Curr. Opin. Biotechnol.14 (6), 621–626 (2003).
   PubMed Web of Science ®Google Scholar
• Fischbach MA , WelshCT. Antibiotics for emerging pathogens. Science325 (5944), 1089–1093 (2009).
   PubMed Web of Science ®Google Scholar
• Gallant P , FinnJ, KeithD, WendlerP. The identification of quality antibacterial drug discovery targets: a case study with aminoacyl-tRNA synthetases. Expert Opin. Ther. Targets4 (1), 1–9 (2000).
   Google Scholar
• Navratilova I , HopkinsAL. Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett.1 (1), 44–48 (2010).
   PubMed Web of Science ®Google Scholar
• Wielens J , HeadeySJ, RhodesDIet al. Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification? J. Biomol. Screen. 18 (2), 147–159 (2013).
   PubMed Web of Science ®Google Scholar
• Siegal G , AbE, SchultzJ. Integration of fragment screening and library design. Drug Discov. Today12 (23–24), 1032–1039 (2007).
   PubMed Web of Science ®Google Scholar
• Mayr LM , BojanicD. Novel trends in high-throughput screening. Curr. Opin. Pharmacol.9 (5), 580–588 (2009).
   PubMed Web of Science ®Google Scholar
• Valler MJ , GreenD. Diversity screening versus focussed screening in drug discovery.Drug Discov. Today5 (7), 286–293 (2000).
   PubMed Web of Science ®Google Scholar
• Walters WP , StahlMT, MurckoMA. Virtual Screening - an overview.Drug Discov. Today3 (4), 160–178 (1998).
   Web of Science ®Google Scholar
• Marriott DP , DugallIG, MeghaniP, LiuYJ, FlowerDR. Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarin M(3) receptor antagonists. J. Med. Chem.42 (17), 3210–3216 (1999).
   PubMed Web of Science ®Google Scholar
• Boucher HW , TalbotGH, BradleyJSet al. Bad bugs, no drugs: no eskape! An update from infectious diseases society of America. Clin. Infect. Dis.48 (1), 1–12 (2009). 
   PubMed Web of Science ®Google Scholar
• Storz MP , MaurerCK, ZimmerCet al. Validation of PqsD as an anti-biofilm target in Pseudomonas aeruginosa by development of small-molecule inhibitors. JACS134 (39), 16143–16146 (2012).
   PubMed Web of Science ®Google Scholar
• Alhamadsheh MM , WatersNC, SachdevaS, LeeP, ReynoldsKA. Synthesis and biological evaluation of novel sulfonyl-naphtalene-1,4-diols as FabH inhibitors. Bioorg. Med. Chem. Lett.18 (24), 6402–6405 (2008).
   PubMed Web of Science ®Google Scholar
• Daines RA , PendrakI, ShamKet al. First x-ray cocrystal structure of a bacterial FabH condensing enzyme and a small molecule inhibitor achieved using rational design and homology modeling. J. Med. Chem. 46 (1), 5–8 (2003).
   PubMed Web of Science ®Google Scholar
• Al-Balas Q , AnthonyNG, Al-JaidiBet al. Identification of 2-aminothiazole-4-carboxylate derivates active against Mycobacterium tuberculosis H37Rv and the beta-keto-ACP synthase mtFabH. PloS ONE4 (5), e5617 (2009).
   PubMed Web of Science ®Google Scholar
• Senior SJ , IllarionovaPA, GurchaSSet al. Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme. Bioorg. Med. Chem. Lett.13 (21), 3685–3688 (2003). 
   PubMed Web of Science ®Google Scholar
• Kim P , ZhangYM, ShenoyGet al. Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli. J. Med. Chem.49 (1), 159–171 (2006). 
   PubMed Web of Science ®Google Scholar
• Nie Z. , PerrettaC, LuJet al. Structure-based design, synthesis, and study of potent inhibitors of beta-ketoacyl-acyl carrier protein synthase III as potential antimicrobial agents. J. Med. Chem.48 (5), 1596–1609 (2005).
   PubMed Web of Science ®Google Scholar
• Bera AK , AtanasovaV, RobinsonHet al. Structure of PqsD, a Pseudomonas quinolone signal biosynthetic enzyme, in complex with anthranilate. Biochem.48 (36), 8644–8655 (2009).
   PubMed Web of Science ®Google Scholar
• Weidel E , De JongJC, BrengelCet al. Structure optimization of 2-benzamidobenzoic acids as PqsD inhibitors for Pseudomonas aeruginosa infections and elucidation of binding mode by SPR, STD NMR, and molecular docking. J. Med. Chem.56 (15), 6146–6155 (2013).
   PubMed Web of Science ®Google Scholar
• Storz MP , BrengelC, WeidelEet al. Biochemical and biophysical analysis of a chiral PqsD inhibitor revealing tight-binding behavior and enantiomers with contrary thermodynamic signatures. ACS Chem. Biol.8 (12), 2794–2801 (2013).
   PubMed Web of Science ®Google Scholar
• Davies C , HeathRJ, WhiteSW, RockCO. The 1.8 angstrom crystal structure and active-site architecture of beta-ketoacyl-acyl carrier protein synthase III (FabH) from Escherichia coli. Structure8 (2), 185–195 (2000).
   PubMed Web of Science ®Google Scholar
• Pistorius D , UllrichA, LucasS, HartmannRW, KazmaierU, MüllerR Biosynthesis of 2-alkyl-4(1H)-quinolones in Pseudomonas aeruginosa: potential for therapeutic interference with pathogenicity. Chembiochem12 (6), 850–853 (2011).
   PubMed Web of Science ®Google Scholar
• Henn C , BoettcherS, SteinbachA, HartmannRW Catalytic enzyme activity on a biosensor chip: combination of surface plasmon resonance and mass spectrometry. Anal. Biochem428 (1), 28–30 (2012). 
   PubMed Web of Science ®Google Scholar
• Zhang JH , ChungTDY, OldenburgKR. A simple statistic parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen.4 (2), 67–73 (1999).
   PubMed Web of Science ®Google Scholar
• Jones G , WillettP, GlenRC, LeachAR, TaylorR. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol.267 (3), 727–748 (1997).
   PubMed Web of Science ®Google Scholar
• Verdonk ML , ColeJC, HartshornMJ, MurrayCW, TaylorRD. Improved protein-ligand docking using GOLD. Proteins52 (4), 609–623 (2003).
   PubMed Web of Science ®Google Scholar
• Molecular Operating Environment (MOE)2010.10. Chemical Computing Group, Quebec, Canada (2010).
   Google Scholar
• Perspicace S , BannerD, BenzJ, MüllerF, SchlatterD, HuberW. Fragment-based screening using surface plasmon resonance technology. J. Biomol. Screen.14 (4), 337–349 (2009).
   PubMed Web of Science ®Google Scholar
• Giannetti AM , KochBD, BrownerMF. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors. J. Med. Chem.51 (3), 574–580 (2008).
   PubMed Web of Science ®Google Scholar
• Rees DC , CongreveM, MurrayCW, CarrR. Fragment-based lead discovery. Nat. Rev. Drug Discov.3 (8), 660–672 (2004). 
   PubMed Web of Science ®Google Scholar
• Yuan YQ , LeedsJA, MeredithTC. Pseudomonas aeruginosa directly shunts beta-oxidation degradation intermediates into de novo fatty acid biosynthesis. J. Bacteriol.194 (19), 5185–5196 (2012). 
   PubMed Web of Science ®Google Scholar
• Yuan YQ , SachdevaM, LeedsJA, MeredithTC. Fatty acid biosynthesis in Pseudomonas aeruginosa is initiated by the FabY class of beta-ketoacyl acyl carrier protein synthases. J. Bacteriol.194 (19), 5171–5184 (2012).
   PubMed Web of Science ®Google Scholar
• Shelat AA , GuyRK. Scaffold composition and biological relevance of screening libraries.. Nat. Chem. Biol.3 (8), 442–446 (2007).
   PubMed Web of Science ®Google Scholar
• Hann MM , LeachAR, HarperG. Molecular complexity and its impact on the probability of finding leads for drug discovery;. J. Chem. Inf. Comput. Sci.41 (3), 856–864 (2001).
   PubMedGoogle Scholar
• Hopkins AL , GroomCR, AlexA. Ligand efficiency: a useful metric for lead selection. Drug Discov. Today9 (10), 430–431 (2004).
   PubMed Web of Science ®Google Scholar
• Howard S , BerdiniV, BoulstridgeJAet al. Fragment-based discovery of the pyrazol-4-yl-urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J. Med. Chem.52 (2), 379–388 (2009).
   PubMed Web of Science ®Google Scholar
• Villemagno B , FlipoM, BlondiauxNet al. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging and linking approaches. J. Med. Chem.57 (11), 4876–4888 (2014).
   PubMed Web of Science ®Google Scholar
• Johnson CN , BerdiniV, BekeLet al. Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase. J. Med. Chem. Lett. (2014) ( Epub ahead of print).
   Google Scholar
• Sahner JH , BrengelC, StorzMPet al. Combining in silico and biophysical methods for the development of Pseudomonas aeruginosa quorum sensing inhibitors: an alternative approach for structure-based drug design. J. Med. Chem.56 (21), 8656–8664 (2013).
   PubMed Web of Science ®Google Scholar